Oncopeptides expands WODA partnership with addition of Africa and Eurasia

Oncopeptides and Veld Pharmaceuticals GmbH (“Veld”) and Slavpharma GmbH (“Slavpharma”) has announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti in Sub-Saharan Africa, with focus on South Africa, as the company communicated during the presentation of its report for the second quarter, and Eurasia.

Under the terms of this exclusive agreement, Veld and Slavpharma will distribute Pepaxti to patients in their respective regions for the treatment of patients with multiple myeloma. The parties have agreed on a revenue split on all Pepaxti sales in the region, with Veld and Slavpharma carrying all costs through their existing structure in the region. All sales will be made on a named patient basis, meaning doctors request supply of Pepaxti directly from the manufacturer, a method of sales similar to that being employed by Oncopeptides in Greece and MENA.

“I am excited to announce this expansion of the original MENA territories, now into Africa and Eurasia, with Oncopeptides,” says WODA Chairman Patrick Jordan. “Multiple Myeloma continues to be a difficult hematological disease that requires a host of therapies to fight back against the disease. In offering Pepaxti, a drug that is fully approved in the EU, to Health Care Providers beyond MENA and Europe, they will now have an important and complementing tool in the arsenal to help treat patients in need.”

“We continue to experience an unmet medical need and a demand for our drug also outside of Europe, and our partnership with Veld and Slavpharma allow us to expand the footprint of where in the world we are able to help patients,” says Sofia Heigis, CEO of Oncopeptides.